Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries

Craven, Philip; Aimon, A.; Dow, Mark; Fleury‐Brégeot, Nicolas; Guilleux, Rachel; Morgentin, Rémy; Roche, Didier; Kalliokoski, Tuomo; Foster, Richard; Marsden, Stephen P.; Nelson, Adam

doi:10.1016/j.bmc.2014.12.048

Cited by 27 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, a significant number of unprecedented spiro, bridged, and fused polycycles with different degrees of saturation, conjugation, and substitution have been synthesized and expanded to a library format. This has been recently exemplified by several publications from the ELF chemistry groups detailing the associated design and validation aspects [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]. Given that most theoretical ring systems remains unexplored [39], the synthesis of novel rings represents one of the strategies embraced by the ELF chemistry consortium to expand the available chemical space.…”

Section: Page 5 Of 11mentioning

confidence: 99%

Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective

Karawajczyk¹,

Giordanetto²,

Benningshof³

et al. 2015

Drug Discovery Today

Self Cite

View full text Add to dashboard Cite

High-throughput screening (HTS) represents a major cornerstone of drug discovery. The availability of an innovative, relevant and high-quality compound collection to be screened often dictates the final fate of a drug discovery campaign. Given that the chemical space to be sampled in research programs is practically infinite and sparsely populated, significant efforts and resources need to be invested in the generation and maintenance of a competitive compound collection. The European Lead Factory (ELF) project is addressing this challenge by leveraging the diverse experience and know-how of academic groups and small and medium enterprises (SMEs) engaged in synthetic and/or medicinal chemistry. Here, we describe the novelty, diversity, structural complexity, physicochemical characteristics and overall attractiveness of this first batch of ELF compounds for HTS purposes.

show abstract

Section: Page 5 Of 11mentioning

confidence: 99%

Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective

Karawajczyk¹,

Giordanetto²,

Benningshof³

et al. 2015

Drug Discovery Today

Self Cite

View full text Add to dashboard Cite

show abstract

“…These challenges notwithstanding, the scientists of ELF Chemistry Consortium have developed key approaches that can facilitate novel bioactive molecule discovery, including diversity-oriented synthesis, biology-oriented synthesis, multicomponent chemistry and activity-directed synthesis, as recently described for selected examples [23][24][25][26][27][28][29][30][31][32][33][34] . The innovative chemical approaches taken by the ELF Chemistry Consortium are yielding novel, diverse and distinctive compounds that will complement existing large compound collections used for high throughput screening drug discovery applications, thus serving as a blueprint for future compound collection enhancement campaigns.…”

Section: Challengesmentioning

confidence: 99%

The European lead factory—an experiment in collaborative drug discovery

Laverty

Orrling

Giordanetto³

et al. 2016

J Med Dev Sci

View full text Add to dashboard Cite

The European lead factory-an experiment in collaborative drug discovery. © 2015 Hugh Laverty, et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 20 REVIEW ARTICLEThe European lead factory-an experiment in collaborative drug discovery Abstract: The European Lead Factory (ELF) is a unique collaborative public-private partnership aiming to deliver innovative drug discovery starting points and improving the value generated by ultra-High Throughput Screening (uHTS) approaches. Composed of a unique compound collection derived from private pharmaceutical company collections and complemented with new chemistries from a unique public collection, it offers a unique uHTS platform accessible to both private companies and publicly funded researchers. One of the key challenges in setting up ELF has been to balance access to screening results with protecting the value of compounds in the collection. Through an 'honest data broker' data management platform and a royalty reward scheme based on achieved milestones, ELF has been able to overcome these challenges. Set up in 2013, it has already accepted 42 targets for screening, submitted by publicly funded researchers, and generated 12 Qualified Hit Lists. In addition, 55,000 new library compounds have been generated by the public partners and added to the 320,000 compounds made available by the companies. Although it faced many challenges in becoming operational, this unique experiment in collaboration is already generating exciting results that will hopefully, eventually lead to better medicines and tools to advance our biological knowledge, and should act as a template for future approaches in the area.

show abstract

“…The presence of silver salt was crucial because in its absence the reaction failed at room temperature (Table 1, entry 1). When the reaction was performed in toluene, compound 1a was obtained as a 3:1 cis/trans pure mixture independently of the silver salt employed (Table 1, entries [2][3][4][5][6][7]. All the silver salts tested such as AgSbF 6 , AgOTf (OTf = triflate), AgOTfa (OTfa = trifluoroacetate), AgOBz, and Ag 2 CO 3 afforded good conversions with very pure crude products.…”

Section: Tetrahedronmentioning

confidence: 99%

“…1,3-Dipolar cycloadditions (1,3-DC) 5,6 involving metallo-azomethine ylides and electrophilic alkenes are appropriate to execute this three concepts with high efficiency. 7 With this favourable features, examples of multicomponent 1,3-DC of azomethine ylides are frequently described nowadays. 8,9 Firstly, the 1,3-dipole precursor (normally an imino ester) can be obtained in situ by imine formation from the corresponding aldehyde and the α-amino ester.…”

mentioning

confidence: 99%

Silver-catalysed multicomponent 1,3-dipolar cycloaddition of 2-oxoaldehydes-derived azomethine ylides

et al. 2015

View full text Add to dashboard Cite

show abstract

Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries

Cited by 27 publications

References 35 publications

Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective

Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective

The European lead factory—an experiment in collaborative drug discovery

Silver-catalysed multicomponent 1,3-dipolar cycloaddition of 2-oxoaldehydes-derived azomethine ylides

Contact Info

Product

Resources

About